Last edition
News about "Sézary syndrome"
Sobi-Innate Pharma Partnership Advances Lacutamab Phase 3 Study
The partnership between Sobi and Innate Pharma will support the TELLOMAK-3 confirmatory Phase 3 trial in CTCL and development of lacutamab in Sézary syndrome.
Sézary Syndrome | 18/09/2026 | By News Bureau
Innate Pharma Partners with Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma and Sobi have partnered to advance lacutamab in T-cell lymphoma, with Innate leading the TELLOMAK-3 phase 3 trial in CTCL.
Sézary Syndrome | 11/08/2026 | By News Bureau
Sobi and Innate Pharma Partner to Advance Lacutamab in T-Cell Lymphoma
Sobi and Innate Pharma partners to advance lacutamab into the TELLOMAK-3 Phase 3 trial, supporting its potential accelerated approval in Sézary syndrome and future development across cutaneous T-cell lymphoma.
Sézary Syndrome | 10/08/2026 | By News Bureau | 143
Innate Pharma Secures FDA Granted BTD for Lacutamab
The BTD is granted based on Phase 1 study results as well as results from the Phase 2 TELLOMAK study, where lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome.
Sézary Syndrome | 18/02/2025 | By Aishwarya | 437
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy